Observational studyThe Journal of international medical research2026
Role of hepatocyte-derived fibrinogen-related protein 1 as a serum biomarker in the diagnosis of community-acquired pneumonia and sepsis: A cross-sectional study.
Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Hepatocyte-Derived Fibrinogen-Related Protein-1: A Novel Biomarker for Severity and Clinical Outcome in Acute Ischemic Stroke.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aimed to evaluate the potential of hepatocyte-derived fibrinogen-related protein 1 (HFREP1) as a biomarker for community-acquired pneumonia and community-acquired pneumonia secondary to sepsis.MethodThis cross-sectional observational study included 124 patients with community-acquired pneumonia, 52 patients with community-acquired pneumonia-sepsis, and 123 healthy controls. Clinical data were collected, including procalcitonin and C-reactive protein levels. Serum HFREP1 concentrations were measured, and statistical analyses were performed.ResultHFREP1 levels differed significantly among the healthy control, community-acquired pneumonia, and community-acquired pneumonia-sepsis groups (37.2 vs. 211.6 vs. 696.8 ng/mL). Binary logistic regression analysis identified procalcitonin and HFREP1 as independent predictors of community-acquired pneumonia-sepsis, while C-reactive protein was not an independent predictor. The area under the curve for HFREP1 in distinguishing community-acquired pneumonia patients from healthy controls was 0.8810. For differentiating community-acquired pneumonia-sepsis from community-acquired pneumonia, the area under the curves were 0.8814 for HFREP1, 0.8167 for C-reactive protein, and 0.8902 for procalcitonin.ConclusionHFREP1 may serve as a biomarker for community-acquired pneumonia and community-acquired pneumonia-sepsis. In community-acquired pneumonia-sepsis, HFREP1 was strongly correlated with C-reactive protein and procalcitonin, and its diagnostic performance was comparable to that of procalcitonin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.